Study Number:	I10482
Study Gender:	Female
PWG Approval Date:	See web page for date of PWG Approval
Version:	v1.0.9

Study Number: I10482
Test Type: TOX
Route: Dosing in Feed
Species/Strain: Mouse/B6C3F1/N

M12: Cytotoxic T Cell Activity
Test Compound: N-Butylbenzenesulfonamide
CAS Number: 3622-84-2

Date Report Requested: 11/04/2020
Time Report Requested: 14:10:10
Lab: Burleson Research Technologies

	Females: CTL						
	Treatment Groups (ppm)						
	0	313	625	1250	2500	5000	50 mg/kg CPS
CTL Activity (5:1)[a]	18.81 ± 3.41 (7) **	27.79 ± 3.36 (8)	24.54 ± 4.82 (7)	38.12 ± 2.36 (8) **	35.91 ± 7.51 (7) *	37.65 ± 4.37 (7) **	1.19 ± 0.98 (2) *
CTL Activity (10:1)	38.12 ± 6.44 (7)	37.93 ± 3.20 (8)	41.37 ± 6.71 (7)	45.77 ± 2.28 (8)	46.05 ± 6.76 (7)	50.31 ± 3.91 (7)	NR
CTL Activity (20:1)	51.50 ± 9.53 (6) *	52.54 ± 3.52 (8)	56.02 ± 12.48 (4)	60.97 ± 2.56 (7)	64.67 ± 6.17 (6)	66.33 ± 5.15 (7)	NR

LEGEND

Data are displayed as mean ± SEM (N) unless otherwise noted.
Data displayed as a mean of (effector cell:target cell ratio)
CTL - Cytotoxic T Lymphocytes
[a]CTL Activity is expressed as % target cell killing calculated as (sample Cr51 release - spontaneous Cr51 release / total Cr51 release - spontaneous Cr51 release)
Statistical analysis performed by Jonckheere (trend) and Shirley or Dunn (pairwise) tests.
Statistical analysis for the positive control group compared to the vehicle control group was performed using the Kruskal-Wallis test.
Statistical significance for the control group indicates a significant trend test
Statistical significance for a treatment group indicates a significant pairwise test compared to the vehicle control group
* Statistically significant at P <= 0.05
** Statistically significant at P <= 0.01
CPS = Cyclophosphamide
NR not recorded

** END OF REPORT **